Crinetics Pharmaceuticals, Inc.
CRNX
Rank in Stocks
#2248
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Share Price
$84.95
Last synced: 2026-09-01
Market Cap
$9.00B
Change (1 day)
0.00%
Change (1 year)
100.12%
Country
US
Trade Crinetics Pharmaceuticals, Inc. (CRNX)
Category
Healthcare
Earnings for Crinetics Pharmaceuticals, Inc. (CRNX)
Earnings in Jun 2026 TTM: $-501.43M
According to Crinetics Pharmaceuticals, Inc. latest financial reports the company's current earnings are $-501.43M. In 2023 the company made an earning of $-214.53M, a decrease compared to its 2022 earnings that were of $-163.92M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Crinetics Pharmaceuticals, Inc. from 2016 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-501.43M | 68.03% |
| 2024 | $-298.41M | 39.10% |
| 2023 | $-214.53M | 30.88% |
| 2022 | $-163.92M | 52.28% |
| 2021 | $-107.64M | 45.83% |
| 2020 | $-73.81M | 46.39% |
| 2019 | $-50.42M | 85.96% |
| 2018 | $-27.12M | 196.11% |
| 2017 | $-9.16M | 52.13% |
| 2016 | $-6.02M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -1,151.98% |
US
|
|
| $-3.09B | 515.64% |
US
|
|
| $-4.02B | 700.95% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -489.02% |
NL
|
